I emailed the BK trustee, George Miller, and asked whether these grant-funded studies would in any way affect the value of the IP. If anyone feels like backing me up, feel free. Just to review (and sorry to repeat), when Dr. Mullan and I spoke on the phone in mid-November, he pointed out that Roskamp could use anatabine citrate in any clinical trials for free, because the institute is a non-profit. But he said once it is offered for sale, "that's a different story."
This strengthens my thought that Archer Pharma will team up with Roskamp somehow to bid on the IP. If anyone does email Miller and gets a response, I hope you'll let us know. I did not, but at least one poster here did once get a response from him. Can't remember who.
